PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1394147
PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1394147
The global Shrimp Disease Diagnostics Market is poised for remarkable growth, with revenues reaching approximately US$ 484.0 Million in 2024 and a projected valuation of about US$ 800.0 Million by the end of 2031, according to recent report by Fairfield Market Research. This thriving sector is a vital component of the animal diagnostics industry, propelled by the surging global demand for shrimp.
The escalating demand for shrimp, a staple in global seafood consumption, has been a driving force behind the expansion of the shrimp disease diagnostics market. Shrimp aquaculture is crucial for human food and nutrition supply, and this demand is driven by both marine and freshwater shrimp production. Shrimp disease diagnostics play a pivotal role in maintaining the health of shrimp populations, preventing the spread of infectious diseases, and safeguarding the sustainability of shrimp farming.
In particular, the market has witnessed an increased focus on early disease detection, especially for threats like White Spot Syndrome (WSS), where therapeutic options are currently limited. Advanced diagnostic tools, such as PCR and DNA hybridization, have been instrumental in enhancing biosecurity and promoting best management practices in shrimp farming.
Despite its promising growth trajectory, the shrimp disease diagnostics market faces several challenges. The centralized nature of disease detection in laboratories can be costly and time-consuming, demanding specialized facilities and skilled personnel. Regulatory frameworks for shrimp disease diagnostics are still evolving in some regions, potentially impeding market growth.
In addition, the need for enhanced capacity in developing nations, such as those in Asia, to carry out quarantine, surveillance, and disease identification is critical to mitigate disease transmission risks associated with live animal importation. Some regions have already implemented management regulations to protect domestic crustacean populations and ensure sustainable practices.
United States: The U.S. market is set to expand the global market due to its access to advanced molecular diagnostic tools. Factors such as a higher prevalence of infections, rising healthcare expenditure, efficient healthcare infrastructures, and skilled laboratory technicians are contributing to market growth. Collaborations within the aquaculture industry are furthering the focus on health management and disease prevention.
China: As the world's largest consumer of seafood, China is a dominant player in shrimp farming and disease diagnostics. Government regulations ensure seafood safety and quality, prompting an increased demand for disease diagnostics to comply with these standards. Innovations like real-time PCR and ELISA assays have enhanced diagnosis accuracy and speed, further driving adoption.
Germany: Germany's significant seafood market and rising shrimp demand have led to a greater need for effective disease diagnostics. The presence of key market players in the shrimp disease diagnostics market has increased product availability and competition. The incidence of shrimp diseases in the region, including WSSV, YHV, and TSV, has also surged.
Key players in the shrimp disease diagnostics market are actively collaborating with ISO-accredited government laboratories and universities to develop and commercialize innovative diagnostic products. These collaborations aim to leverage advanced technologies for manufacturing genetic diagnostics tools.
Notable companies in the market include: